TRCT
ARTV

Tower Research Capital (TRC)’s Artiva Biotherapeutics ARTV Stock Holding History

Tower Research Capital (TRC)’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.4K Buy
+247
New +$2.25K ﹤0.01% 4670
2026
Q1 		– Sell
-1,103
Closed -$4.73K – 5656
2025
Q4 		$4.73K Sell
1,103
-8,878
-89% -$33.5K ﹤0.01% 4182
2025
Q3 		$28.6K Sell
9,981
-117
-1% -$313 ﹤0.01% 2981
2025
Q2 		$15.2K Buy
10,098
+7,484
+286% +$15.7K ﹤0.01% 3820
2025
Q1 		$7.84K Buy
2,614
+1,402
+116% +$7.57K ﹤0.01% 3930
2024
Q4 		$12.2K Buy
1,212
+492
+68% +$5.91K ﹤0.01% 3639
2024
Q3 		$11.1K Buy
+720
New +$8.34K ﹤0.01% 3692

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Tower Research Capital (TRC)'s ARTV Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 247 shares worth $2.4K. The stake represents ﹤0.01% of the portfolio and ranks #4670 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in ARTV as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $28.6K in Q3 2025. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Tower Research Capital (TRC) held 247 shares of Artiva Biotherapeutics worth $2.4K as of Q2 2026.
  • Artiva Biotherapeutics was a new Tower Research Capital (TRC) position in Q2 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4670 holding.
  • Tower Research Capital (TRC) first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • Tower Research Capital (TRC)'s Artiva Biotherapeutics position peaked at $28.6K in Q3 2025.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.